Pharmaceutical

Elahere secures full approval from FDA for types of ovarian cancer

The FDA granted accelerated approval for the drug back in November 2022, and granted priority review in December 2023.

Mar 26, 2024 - 00:00
Elahere secures full approval from FDA for types of ovarian cancer
The FDA granted accelerated approval for the drug back in November 2022, and granted priority review in December 2023.
Read the original article

Tags:

Previous Article

Novo shells out $1.1bn to buy Cardior to expand cardiovascular pipeline

Next Article

CRISPR-based assay could revolutionise diagnosis of NTM infections

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

US FDA approves Daiichi Sankyo’s acute myeloid leukaemia treatment

US FDA approves Daiichi Sankyo’s acute myeloid leukaemi...

Jul 21, 2023

FDA grants ODD to Abdera’s neuroendocrine carcinoma treatment

FDA grants ODD to Abdera’s neuroendocrine carcinoma tre...

Sep 8, 2024

STAT+: FDA oncology head wants advisory panels to keep voting on new drugs

STAT+: FDA oncology head wants advisory panels to keep ...

Jun 6, 2023